Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Immunovaccine Inc (IMV.TO)

Immunovaccine Inc (IMV.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 161,512
  • Shares Outstanding, K 50,631
  • Annual Sales, $ 483 K
  • Annual Income, $ -21,935 K
  • 60-Month Beta 0.95
  • Price/Sales 272.44
  • Price/Cash Flow N/A
  • Price/Book 11.03
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.55
  • Most Recent Earnings -0.16 on 09/30/19
  • Next Earnings Date 11/08/19
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.13
  • Number of Estimates 4
  • High Estimate -0.12
  • Low Estimate -0.15
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +23.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.08 +6.82%
on 10/31/19
4.10 -19.76%
on 10/25/19
-0.11 (-3.24%)
since 10/15/19
3-Month
3.01 +9.30%
on 10/02/19
4.40 -25.23%
on 09/19/19
-0.42 (-11.32%)
since 08/15/19
52-Week
3.01 +9.30%
on 10/02/19
8.49 -61.25%
on 12/03/18
-3.93 (-54.43%)
since 11/15/18

Most Recent Stories

More News
IMV Inc. Announces Third Quarter 2019 Financial Results and Provides Corporate Update

IMV Inc. (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the third quarter ended...

IMV.TO : 3.27 (+2.51%)
Updated Results from Phase 2 SPiReL Study Evaluating IMV's DPX-Survivac as Combination Therapy in Patients with r/r DLBCL to be Presented at 61st American Society of Hematology (ASH) Annual Meeting

--All patients tested were positive for survivin and blood analysis shows strong survivin-specific T cell responses correlated with clinical responses

IMV.TO : 3.27 (+2.51%)
IMV to Present Clinical Translational Data from DeCidE1 Study of DPX-Survivac at SITC 2019 Annual Meeting

--Survivin-specific T cells remain active and proliferative over time, leading to T cell infiltration and the repopulation of up to 90% of the tumor microenvironment

IMV : 2.49 (+3.32%)
IMV.TO : 3.27 (+2.51%)
IMV Appoints Joanne Schindler, M.D., D.V.M. as Chief Medical Officer

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced the appointment of Joanne Schindler, M.D., D.V.M. as its new Chief...

IMV.TO : 3.27 (+2.51%)
IMV Inc. to Announce Third Quarter 2019 Results and Host a Conference Call and Webcast on November 8, 2019

IMV Inc. ("IMV" or the "Corporation") (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, announced today that it will hold a conference call...

IMV.TO : 3.27 (+2.51%)
/ C O R R E C T I O N From Source - IMV Inc /

In the news release issued on October 11, IMV announced that company management presentation at the BIO Investor Forum is scheduled on October 23 at 5:00 PM PST (8:00 PM EST).

IMV.TO : 3.27 (+2.51%)
IMV Inc. to Present at Upcoming Investor Conference

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that company management will be attending the BIO Investor Forum to be held on October 22-23 at the Westin St....

IMV.TO : 3.27 (+2.51%)
Preliminary Results From IMV's Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients With Advanced and Metastatic Solid Tumors to Be Presented at ESMO Congress 2019

--Treatment well-tolerated, with no related Grade 3-4 or immune-related adverse events

IMV.TO : 3.27 (+2.51%)
Preliminary Results From IMV's Phase 2 Basket Trial Evaluating DPX-Survivac as a Combination Therapy in Patients with Advanced and Metastatic Solid Tumors to Be Presented at ESMO Congress 2019

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that preliminary results from its ongoing Phase 2 basket trial, evaluating DPX-Survivac in combination with Merck's...

IMV.TO : 3.27 (+2.51%)
IMV Announces Research Collaboration with The Wistar Institute to Develop New Targeted Immunotherapy Against the Common BRAF Cancer Mutation

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage immuno-oncology company, today announced a collaboration with The Wistar Institute and Meenhard Herlyn, D.V.M., D.Sc., professor in the Molecular and...

IMV.TO : 3.27 (+2.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

2nd Resistance Point 3.44
1st Resistance Point 3.32
Last Price 3.27
1st Support Level 3.13
2nd Support Level 3.06

See More

52-Week High 8.49
Fibonacci 61.8% 6.40
Fibonacci 50% 5.75
Fibonacci 38.2% 5.10
Last Price 3.27
52-Week Low 3.01

See More

Business Summary

IMV Inc is a clinical-stage biopharmaceutical company. The company is engaged in making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. Its proprietary drug development platform provides a patented delivery formulation...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar